Pierfranco Conte focuses on Internal medicine, Oncology, Surgery, Breast cancer and Chemotherapy. His Internal medicine study frequently draws connections to other fields, such as Gastroenterology. Pierfranco Conte combines subjects such as Taxane, Cancer, Survival analysis and Trastuzumab with his study of Oncology.
The concepts of his Surgery study are interwoven with issues in Carcinoma and Urology. His work deals with themes such as Receptor, Metastasis, Adjuvant therapy and Hazard ratio, which intersect with Breast cancer. His research integrates issues of Survival rate and Capecitabine in his study of Metastatic breast cancer.
Pierfranco Conte mainly focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Surgery. His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology. His work on Lung cancer is typically connected to In patient as part of general Oncology study, connecting several disciplines of science.
His Breast cancer study incorporates themes from Adjuvant therapy, Cohort and Hazard ratio. His Chemotherapy research includes elements of Regimen and Ovarian cancer. His Cancer research incorporates themes from Cancer research and Pathology.
Pierfranco Conte mainly investigates Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. Internal medicine is a component of his Metastatic breast cancer, Trastuzumab, Cohort, Hazard ratio and Neoadjuvant therapy studies. As a member of one scientific family, Pierfranco Conte mostly works in the field of Metastatic breast cancer, focusing on Olaparib and, on occasion, BRCA mutation and Vinorelbine.
When carried out as part of a general Oncology research project, his work on Lung cancer is frequently linked to work in In patient, therefore connecting diverse disciplines of study. As part of one scientific family, he deals mainly with the area of Breast cancer, narrowing it down to issues related to the Proportional hazards model, and often Retrospective cohort study. Chemotherapy regimen is the focus of his Chemotherapy research.
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Chemotherapy and Hazard ratio. Many of his studies involve connections with topics such as Placebo and Internal medicine. His Oncology study combines topics in areas such as Stage, Letrozole and Disease.
The study incorporates disciplines such as Gastroenterology, Clinical endpoint, Estrogen and Cancer staging in addition to Breast cancer. His study on Paclitaxel is often connected to In patient as part of broader study in Chemotherapy. His research in Hazard ratio focuses on subjects like Proportional hazards model, which are connected to Radiation therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
H. von der Maase;S.W. Hansen;J.T. Roberts;L. Dogliotti.
Journal of Clinical Oncology (2000)
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
Michael Marty;Francesco Cognetti;Dominique Maraninchi;Raymond Snyder.
Journal of Clinical Oncology (2005)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu.
The New England Journal of Medicine (2017)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap.
The New England Journal of Medicine (2016)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
José Baselga;Karen A. Gelmon;Shailendra Verma;Andrew Wardley.
Journal of Clinical Oncology (2010)
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone.
The New England Journal of Medicine (2019)
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
J M Nabholtz;K Gelmon;M Bontenbal;M Spielmann.
Journal of Clinical Oncology (1996)
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
Valentina Guarneri;Antonio Frassoldati;Alberto Bottini;Katia Cagossi.
Journal of Clinical Oncology (2012)
Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
L. A. Stewart;K. Aabo;P. Adnitt;M. Adams.
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale.
Annals of Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: